NASDAQ:SBBP - Strongbridge Biopharma Stock Price, Forecast & News

Strongbridge Biopharma trades on the NASDAQ under the ticker symbol "SBBP."

Strongbridge Biopharma plc (NASDAQ:SBBP) announced its quarterly earnings data on Thursday, November, 7th. The biotechnology company reported ($0.25) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.32) by $0.07. The biotechnology company had revenue of $5.68 million for the quarter, compared to the consensus estimate of $5.06 million. Strongbridge Biopharma had a return on equity of 45.77% and a net margin of 211.37%. View Strongbridge Biopharma's Earnings History.

Strongbridge Biopharma is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for Strongbridge Biopharma.

Strongbridge Biopharma updated its FY 2019 Pre-Market earnings guidance on Monday, November, 25th. The company provided EPS guidance of for the period. The company issued revenue guidance of $$18-20 million, compared to the consensus revenue estimate of $$20.82 million.

5 brokerages have issued 1-year price objectives for Strongbridge Biopharma's stock. Their forecasts range from $8.00 to $18.00. On average, they expect Strongbridge Biopharma's share price to reach $13.25 in the next twelve months. This suggests a possible upside of 383.6% from the stock's current price. View Analyst Price Targets for Strongbridge Biopharma.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Strongbridge Biopharma in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Strongbridge Biopharma.

Media stories about SBBP stock have trended somewhat positive recently, InfoTrie reports. InfoTrie rates the sentiment of press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Strongbridge Biopharma earned a media sentiment score of 1.5 on InfoTrie's scale. They also assigned media headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the near future. View News Stories for Strongbridge Biopharma.

Strongbridge Biopharma saw a decrease in short interest in the month of December. As of December 31st, there was short interest totalling 518,500 shares, a decrease of 19.8% from the December 15th total of 646,400 shares. Based on an average daily volume of 422,500 shares, the short-interest ratio is presently 1.2 days. Approximately 1.5% of the shares of the stock are sold short. View Strongbridge Biopharma's Current Options Chain.

Some companies that are related to Strongbridge Biopharma include Kadmon (KDMN), Kura Oncology (KURA), Akero Therapeutics (AKRO), Crinetics Pharmaceuticals (CRNX), Prothena (PRTA), MacroGenics (MGNX), Clovis Oncology (CLVS), Viking Therapeutics (VKTX), Magenta Therapeutics (MGTA), BioDelivery Sciences International (BDSI), Neoleukin Therapeutics (NLTX), OrganiGram (OGI), Molecular Templates (MTEM), Dynavax Technologies (DVAX) and Organogenesis (ORGO).

Based on aggregate information from My MarketBeat watchlists, some companies that other Strongbridge Biopharma investors own include Energy Transfer LP Unit (ET), Genocea Biosciences (GNCA), Dicerna Pharmaceuticals (DRNA), SCYNEXIS (SCYX), Viking Therapeutics (VKTX), Agile Therapeutics (AGRX), Abeona Therapeutics (ABEO), Opko Health (OPK), Ovid Therapeutics (OVID) and Sorrento Therapeutics (SRNE).

Strongbridge Biopharma's stock is owned by a number of of retail and institutional investors. Top institutional investors include Diversified Trust Co (0.37%) and Wiley BROS. Aintree Capital LLC (0.03%). View Institutional Ownership Trends for Strongbridge Biopharma.

SBBP stock was bought by a variety of institutional investors in the last quarter, including Diversified Trust Co and Wiley BROS. Aintree Capital LLC. View Insider Buying and Selling for Strongbridge Biopharma.

Shares of SBBP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of SBBP stock can currently be purchased for approximately $2.74.

Strongbridge Biopharma has a market capitalization of $148.52 million and generates $18.03 million in revenue each year. The biotechnology company earns $31.85 million in net income (profit) each year or $0.31 on an earnings per share basis. Strongbridge Biopharma employs 106 workers across the globe.View Additional Information About Strongbridge Biopharma.

The official website for Strongbridge Biopharma is http://www.strongbridgebio.com/.

Strongbridge Biopharma's mailing address is 900 NORTHBROOK DRIVE SUITE 200, TREVOSE PA, 19053. The biotechnology company can be reached via phone at 610-254-9200 or via email at [email protected]